The FDA recently approved BYDUREON BCise (an extended-release version of the GLP-1 drug, exenatide) for teens with type 2 diabetes. Recently published data shows disturbingly high rates and serious diabetes complications in people who develop type 2 diabetes at a young age suggesting the need for aggressive early treatment and more treatment options. Continue Reading »